

DearFrom: Cathy Moore

Sent: 01 May 2007 10:28

To: Reetan Patel

Subject: FW: Coronary artery stents for the treatment of ischaemic heart disease (review of NICE technology appraisal guidance no. 71)

Importance: High

Attachments: NICETAR DES Addendum clopidogrel costs for C&Cs 05 04 07
NO CIC.DOC; NICETAR DES Addendum-Suppl for C&Cs 23 05 06 NO
CIC.DOC

Dear Reetan

Re: Coronary Artery Stents for the Treatment of Ischaemic Heart Disease
(review of NICE technology appraisal guidance No 71)

Please note that Action Heart has no comments to make on the additional analysis detailed in the attached documents.

Kind Regards

Cathy Moore

From: Russell Tipson

Sent: 15 April 2007 20:21

To: Cathy Moore

Subject: FW: Coronary artery stents for the treatment of ischaemic heart disease (review of NICE technology appraisal guidance no. 71)

From: Reetan Patel

Sent: 11 April 2007 09:31

To: Reetan Patel

Cc: Laura Bridgman; Philip Ranson

Subject: Coronary artery stents for the treatment of ischaemic heart disease
(review of NICE technology appraisal guidance no. 71)

11 April 2007

MidCity Place

71 High Holborn

London

WC1V 6NA

Email: nice@nice.org.uk

www.nice.org.uk

Dear Consultee/Commentator

Health Technology Appraisal

Coronary artery stents for the treatment of ischaemic heart disease (review of NICE technology appraisal guidance no. 71)

Further to the letter sent to you via email on 12 March 2007 with the specification for the additional analysis, please find attached additional analysis produced by the Assessment Group (Liverpool Reviews &

Implementation Group, University of Liverpool).

At the request of the Committee, some additional work was commissioned following the meeting in February 2006. Due to uncertainty over a number of the parameters that had been included in the assessment group's model some of the values were varied, taking account of some additional data that had been discussed at the meeting and examining further the issue of sub-groups. This additional work (Addendum 3') was consulted on in April 2006.

1. Following the comments received from consultation further sensitivity analyses were undertaken (see attached, Addendum supplement 3"). These analyses did not include any additional clopidogrel costs as it was assumed that the duration of clopidogrel (and therefore the costs) would be the same for bare-metal stents (BMS) and drug-eluting stents (DES) (3 months). Following the recent concerns over the safety of DES these sensitivity analyses have been extended to examine how the difference in the duration of clopidogrel use between BMS and DES may affect the cost effectiveness (see attached, Addendum 4'). This reflects recommendations made by the American Heart Association and the British Cardiovascular Intervention Society, that the duration of use of anti-platelet therapy (aspirin and clopidogrel) should be extended in patients who have received a DES to at least 12 months, and in particular in those patients whose lesions are thought to be high risk.

I am writing to invite your comments on the both pieces of additional analysis prior to the meeting of the Appraisal Committee on 4 July 2007 when this technology will be considered further. All comments received from consultees and commentators on the analyses will be incorporated into an evaluation report for consideration by the Committee at this meeting. The deadline for receipt of comments is 5pm on 10 May 2007.

We prefer to receive your comments in electronic format, either by email or on compact or floppy disk, although we can also accept printed documents. Please send your comments to Reetan Patel, Technology Appraisal Project Manager, by email to reetan.patel@nice.org.uk.

I must emphasise that the documents attached and its contents are confidential. It is released to you only for the purpose of informing the Appraisal Committee's consideration of these technologies. Accordingly, neither the documents nor its contents should be divulged to anyone other than those individuals within your organisation who need to see to them to enable you to prepare your response. Those to whom you do show the documents must be advised they are bound by the terms of the Confidentiality Acknowledgement and Undertaking Form that has been signed and returned to the Institute by your organisation.

2. Yours sincerely

3.

Carole Longson

Director, Centre for Health Technology Evaluation

Scanned by MessageLabs

Delivered via MessageLabs

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed.

If you have received this email in error please notify the sender by

telephone on 01384 292233 and return it to the sender at the above

address. This message contains confidential information and is intended

only for the individual named. If you are not the named addressee you

should not disseminate, distribute or copy this email.